Ironwood Pharmaceuticals
IRWD
130 hedge funds and large institutions have $1.47B invested in Ironwood Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 44 increasing their positions, 41 reducing their positions, and 21 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
7% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 41
5% less funds holding
Funds holding: 137 → 130 (-7)
15% less capital invested
Capital invested by funds: $1.73B → $1.47B (-$265M)
29% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 21
56% less call options, than puts
Call options by funds: $1.74M | Put options by funds: $3.98M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMC
Rubric Capital Management (Connecticut)
Stamford,
Connecticut
|
+$71.6M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$30.1M |
| 3 |
BM
Bridger Management
New York
|
+$24.9M |
| 4 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$7.95M |
| 5 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$5.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$59M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$47.9M |
| 3 |
O
OrbiMed
New York
|
-$13.1M |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$12.2M |
| 5 |
FAM
Fred Alger Management
New York
|
-$10.6M |
IRWD Hedge Fund Activity: Q3 2015 in Review
130 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q3 2015, worth a combined $1.47B — down 15% from $1.73B a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of IRWD and 15 opened new positions — a net loss of 6 holders — while 41 trimmed existing stakes and 44 added.
The largest buyer was Rubric Capital Management (Connecticut), opening a new position worth an estimated $71.6M. The largest seller was Morgan Stanley, cutting an estimated $59M.
- 130 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q3 2015, down from 137 in Q2 2015.
- Funds reported $1.47B of Ironwood Pharmaceuticals stock for Q3 2015, down 15% quarter-over-quarter.
- 15 funds opened new Ironwood Pharmaceuticals positions in Q3 2015 and 21 closed out, a net change of -6 holders.
- The largest Ironwood Pharmaceuticals buyer in Q3 2015 was Rubric Capital Management (Connecticut), an estimated $71.6M added.
- The largest Ironwood Pharmaceuticals seller in Q3 2015 was Morgan Stanley, an estimated $59M sold.
Based on aggregated 13F filings for Q3 2015.